Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 221

Related Citations for PubMed (Select 24098661)

1.

A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.

Qu X, Randhawa G, Friedman C, Kurland BF, Glaskova L, Coleman I, Mostaghel E, Higano CS, Porter C, Vessella R, Nelson PS, Fang M.

PLoS One. 2013 Sep 30;8(9):e74671. doi: 10.1371/journal.pone.0074671. eCollection 2013.

2.

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS.

Cancer Res. 2009 Apr 1;69(7):2912-8. doi: 10.1158/0008-5472.CAN-08-3667.

3.

A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.

Qu X, Randhawa G, Friedman C, O'Hara-Larrivee S, Kroeger K, Dumpit R, True L, Vakar-Lopez F, Porter C, Vessella R, Nelson P, Fang M.

Cancer Genet. 2013 Jan-Feb;206(1-2):1-11. doi: 10.1016/j.cancergen.2012.12.004. Epub 2013 Jan 24.

4.

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.

Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB, Tolonen TT, Stenman UH, Tammela TL, Nykter M, Bova GS, Visakorpi T.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2333-44. doi: 10.1158/1055-9965.EPI-13-0333-T. Epub 2013 Oct 1.

5.

Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.

Bismar TA, Yoshimoto M, Duan Q, Liu S, Sircar K, Squire JA.

Histopathology. 2012 Mar;60(4):645-52. doi: 10.1111/j.1365-2559.2011.04116.x. Epub 2012 Jan 19.

PMID:
22260502
6.

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.

Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB.

Mod Pathol. 2009 Aug;22(8):1083-93. doi: 10.1038/modpathol.2009.69. Epub 2009 May 1.

7.

Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer.

Udager AM, Shi Y, Tomlins SA, Alva A, Siddiqui J, Cao X, Pienta KJ, Jiang H, Chinnaiyan AM, Mehra R.

Prostate. 2014 Sep;74(12):1199-208. doi: 10.1002/pros.22836. Epub 2014 Jul 7.

8.

ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer.

Scheble VJ, Scharf G, Braun M, Ruiz C, Stürm S, Petersen K, Beschorner R, Bachmann A, Zellweger T, Fend F, Kristiansen G, Bubendorf L, Wernert N, Shaikhibrahim Z, Perner S.

Virchows Arch. 2012 Aug;461(2):157-62. doi: 10.1007/s00428-012-1270-7. Epub 2012 Jul 6.

PMID:
22767266
9.

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.

Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA.

Mod Pathol. 2008 Dec;21(12):1451-60. doi: 10.1038/modpathol.2008.96. Epub 2008 May 23.

10.

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.

Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.

Cancer Res. 2008 May 15;68(10):3584-90. doi: 10.1158/0008-5472.CAN-07-6154.

11.

Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.

Dhani NC, Emmenegger U, Adams L, Jongstra J, Tannock IF, Sridhar SS, Knox JJ, Day JR, Groskopf J, Joshua AM.

BJU Int. 2012 Sep;110(6):840-5. doi: 10.1111/j.1464-410X.2011.10922.x. Epub 2012 Feb 7.

PMID:
22313860
12.

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, Reuter VE, Gerald WL.

Cancer Res. 2009 Feb 15;69(4):1400-6. doi: 10.1158/0008-5472.CAN-08-2467. Epub 2009 Feb 3.

13.

ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer.

Gsponer JR, Braun M, Scheble VJ, Zellweger T, Bachmann A, Perner S, Vlajnic T, Srivastava M, Tan SH, Dobi A, Sesterhenn IA, Srivastava S, Bubendorf L, Ruiz C.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):126-31. doi: 10.1038/pcan.2013.62. Epub 2014 Jan 28.

PMID:
24469092
14.

PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade.

Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS, Joshua AM, Fleshner NE, Squire JA, Evans AJ.

Mod Pathol. 2013 Mar;26(3):435-47. doi: 10.1038/modpathol.2012.162. Epub 2012 Sep 28.

15.
16.

Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.

Cai C, Wang H, Xu Y, Chen S, Balk SP.

Cancer Res. 2009 Aug 1;69(15):6027-32. doi: 10.1158/0008-5472.CAN-09-0395. Epub 2009 Jul 7.

17.

[TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].

Xiao L, Zhu XZ, Wang Y, Gong Y, Guo CC.

Zhonghua Bing Li Xue Za Zhi. 2011 Jun;40(6):392-6. Chinese.

PMID:
21914348
18.

Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R, Lee C, Chinnaiyan AM, Rubin MA.

Neoplasia. 2007 Mar;9(3):200-6.

19.

Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.

Kolar Z, Burdova A, Jamaspishvili T, Bouchal J, Kucerova R, Bienova M, Kral M, Student V.

Neoplasma. 2014;61(1):9-16.

PMID:
24195515
20.

Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.

Fleischmann A, Saramäki OR, Zlobec I, Rotzer D, Genitsch V, Seiler R, Visakorpi T, Thalmann GN.

Prostate. 2014 Dec;74(16):1647-54. doi: 10.1002/pros.22882. Epub 2014 Sep 22.

PMID:
25252136
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk